Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGINTERVENTIONAL

Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases

Efficacy and Safety of Hyperbaric Oxygen Therapy in Adult Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD) Patients : a Randomized Controlled Trial

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The goal of this clinical trial is to learn if hyperbaric oxygen therapy (HBOT) works to treat Metabolic Dysfunction-associated Steatotic Liver Diseases (MASLD). The main questions it aims to answer are: Does HBOT decreases the fat content and fibrosis state of liver in adult MASLD patients? Does HBOT improves the liver function and metabolic condition in adult MASLD patients? Participants will: Receive HBOT for 20 times in 1 month or recerive regular drug; Visit the clinic for checkups and tests at the starting, ending of the therapy and 6 month after the therapy.

Who May Be Eligible (Plain English)

Who May Qualify: - Metabolic dysfunction-associated steatotic liver disease patients Who Should NOT Join This Trial: - Participants are unfit for hyperbaric treatment. - Participants with prior oxygen therapy within the last 6 months. - Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency. - Participants with severe organ dysfunctions or malignant tumors. - Participants have weight loss plan or major operations within the last 6 months. - Participants are unable to provide willing to sign a consent form or currently participating in or has within the last 3 months participated in any other clinical trial. - Participants are pregnant or lactating. - Participants with claustrophobia or that cannot decompress properly. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Metabolic dysfunction-associated steatotic liver disease patients Exclusion Criteria: * Participants are unfit for hyperbaric treatment. * Participants with prior oxygen therapy within the last 6 months. * Participants with history of viral hepatitis, hemochromatosis, Wilson disease, autoimmune hepatitis, primary biliary cirrhosis, sclerosing cholangitis, biliary obstruction, alpha-1 antitrypsin deficiency. * Participants with severe organ dysfunctions or malignant tumors. * Participants have weight loss plan or major operations within the last 6 months. * Participants are unable to provide informed consent or currently participating in or has within the last 3 months participated in any other clinical trial. * Participants are pregnant or lactating. * Participants with claustrophobia or that cannot decompress properly.

Treatments Being Tested

PROCEDURE

Hyperbaric oxygen therapy

Participants receive 20 session of hyperbaric oxygen therapy (HBOT) in one month (inhalation of 100% oxygen in a pressure chamber under 2.0 ATA for 60 minutes).

Locations (1)

General Hospital of Eastern Theater Command
Nanjing, Jiangsu, China